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Continued Use of an Integrated Meter with Electronic
Logbook Maintains Improvements in Glycemic Control
Beyond a Randomized, Controlled Trial
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LUIGI MENEGHINI, M.D.,3 and LISA K. VOLKENING, B.A.1
on behalf of the MONITORING OF BLOOD GLUCOSE STUDY GROUP

ABSTRACT
Background: Blood glucose monitoring is an important component of diabetes self-management for individuals with insulin-treated diabetes. Although patient-maintained logbooks are
routinely used, glucose values may be inaccurately recorded or not recorded at all. Electronic
logbooks may help overcome such problems. We conducted a randomized, controlled trial (RCT)
to compare glycemic control in insulin-treated participants using integrated glucose meters and
electronic logbooks (Electronic Group) with participants using conventional meters and paper
logbooks (Paper Group), and to determine persistence of glycemic improvements during longterm observational follow-up.
Methods: After a 4-week run-in, adult and pediatric participants (n  205) with stable hemoglobin A1C (A1C) 8.0% were randomized, and their logbook data and A1C were monitored
every 4 weeks for 16 weeks. After the RCT, patients selected their monitoring systems and resumed usual care. The four resulting subgroups, defined by whether patients continued or
changed monitoring systems, were reassessed after 26–65 weeks.
Results: During the RCT, mean A1C decreased 0.27% in the Paper Group and 0.35% in
the Electronic Group. Repeated-measures analysis revealed that the mean decrease was significantly greater in the Electronic than the Paper Group (P  0.022). From randomization through
observational follow-up, participants consistently using integrated meters/logbooks had an A1C
decrease of 0.36% (P  0.008), whereas participants using conventional meters/logbooks
throughout or switching meters returned to pre-enrollment A1C levels.
Conclusions: Compared to conventional monitoring systems, use of an integrated meter and
electronic logbook resulted in modest, but significant and sustained, improvement in A1C in insulin-treated patients with suboptimal glycemic control during an RCT and observational follow-up.
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INTRODUCTION

L

PROSPECTIVE CLINICAL TRIALS have
shown that intensive treatment of diabetes
can reduce the risk of chronic complications.1–5
Despite advances in pharmacologic therapies
and monitoring technologies, glycemic control
is suboptimal in the United States, with over
60% of people with diabetes having hemoglobin A1C (A1C) values above 7.0%.6,7
Self-monitoring of blood glucose (SMBG) improves glycemic control in individuals with
poorly controlled insulin-treated diabetes,8–11
and increased monitoring frequency has been
linked to lower A1C values.10,12–20 Although
SMBG with patient-maintained logbooks is
routinely used, glucose values and other data
may be inaccurately recorded.21–23 SMBG meters with electronic logbooks or electronic diaries promote adherence and pattern recognition and may overcome the problems associated
with written logbooks.22
The OneTouch® UltraSmart® System (LifeScan, Milpitas, CA) is an integrated glucose
meter and electronic logbook capable of capturing user comments regarding food intake,
health status, exercise, and insulin doses. The
meter accurately stores blood glucose (BG) results and automatically converts them into
meaningful charts and graphs that can be displayed on the meter directly, thus helping
patients and their health care professionals
(HCPs) determine the impact of medications
and life-style. We conducted a randomized,
controlled trial (RCT) comparing the use of this
integrated meter/logbook with conventional
meters and paper logbooks for their ability to improve glycemic control. In addition, to determine
whether any glycemic improvements noted in
the RCT could be sustained outside the confines
of a clinical trial, we performed an observational
follow-up measurement of A1C approximately
11 months after the end of the RCT.
ARGE

RESEARCH DESIGN AND METHODS
Participants
Investigators from seven centers (nine clinical sites) in the United States recruited adult
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and pediatric (21 years old) patients with
type 1 or insulin-treated type 2 diabetes. Inclusion criteria included a regimen of two or
more daily injections or continuous subcutaneous insulin infusion; suboptimal (A1C 8%)
but stable glycemic control, defined as A1C at
week 4 within 1% of that at enrollment (week
0); and BG monitoring frequency of two or
more times daily. Exclusion criteria included
previous use of OneTouch UltraSmart; risk of
hypoglycemia as a contraindication to improving glycemic control; a regimen of premixed,
fixed-ratio combination insulins with an unwillingness to use self-mixed insulins; and active use of meter downloading and computerbased data management software. Institutional
protocol approval and informed consent/assent were obtained.
Study design and procedures
RCT. Enrollment in the RCT commenced on
August 8, 2003. At enrollment [Study Visit (SV)
1, week 0], participants were informed of the
purpose of the study, and blood was drawn for
A1C analysis. During a 4-week run-in, participants continued using their current BG meters
(14 different meters were used) with written
logbooks. At SV2 (week 4), participants were
randomly assigned to continue using their current meters and paper logbooks (Paper Group),
or to use the integrated glucose meter/logbook
(Electronic Group). A stratified, blinded randomization process ensured balance of participants in each group according to age category
(adult vs. pediatric) and baseline A1C. Participants in the Paper Group received re-education
in the use of their meter and a new meter if
their current meter was not functioning properly, whereas participants in the Electronic
Group were trained in the use of the integrated
meter/logbook, including how to access the
“Graph of All Results” and “Average by Time
of Day” screens in the electronic log, along with
instructions to review these screens with their
HCPs. Participants received equivalent time for
education, and all necessary supplies for
SMBG, regardless of meter assignment. The
HCP determined participant glucose monitoring regimens and treatment decisions independent of study protocol. Participants returned
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monthly for four visits through week 20 (SV6).
At each visit, the participant’s meter was downloaded, blood was drawn for central A1C analysis, and the logbook (electronic or paper), current treatment, and SMBG regimen were
reviewed. Individualized counseling was provided, and treatment recommendations regarding life-style, monitoring regimens, and insulin adjustments were made. All patients and
HCPs were blinded to the results of meter
downloads and A1C determinations until the
end of the RCT.

randomization study visit. All analyses were
conducted using SAS (version 8.2 for Windows,
SAS Institute, Inc., Cary, NC). Means  SD are
presented unless otherwise noted. All statistical tests were two-sided with an  level of 0.05
to determine significance. Comparisons included paired and unpaired t tests, 2 analysis,
and nonparametric tests, where appropriate.
A1C data were analyzed using repeated-measures analysis of variance with baseline A1C,
defined as the value observed at the time of
randomization (SV2), as the covariate.

Observational follow-up. At the last RCT visit
(SV6), participants in the Paper Group were offered the integrated meter and electronic log
system. Participants from both groups returned
to usual medical center or community care, and
all were given the choice of monitoring systems. Glucose monitoring strips were no longer
provided. Patients who had been enrolled at
sites with 30 or more participants, and who had
completed SV6, were recruited to participate in
an observational follow-up visit (SV7). The follow-up visit occurred 26–65 weeks (median
45.9 weeks) after the end of the RCT, at which
time blood was drawn for central A1C measurement. Meter choices made by patients during the observational period were self-reported
at this follow-up visit and verified by the HCP.
The last participant completed the observational follow-up on June 2, 2005.

Observational follow-up. Patient data were divided into four subgroups based on their original randomization into the Paper and Electronic Groups and whether they continued
using the meter they were randomized to or
switched to a different meter. For each subgroup, average A1C at the observational follow-up visit (SV7) was calculated, as was the
average A1C for the patients in that subgroup
at each of the other visits. A1C data were analyzed using paired t tests.

Outcome measures
The primary outcome for both the RCT and
observational follow-up was A1C determination
after randomization. Additional outcomes of the
RCT included SMBG frequency, magnitude of
daily glycemic excursions, and occurrence of
measured hypoglycemia after enrollment. Meter
downloads provided data on frequency of
SMBG; daily glycemic excursions (calculated by
subtracting the lowest BG from the highest BG
measurement within a given day); and the rate
of measured hypoglycemia, defined as any BG
result 60 mg/dL (3.3 mmol/L).
Statistical analysis
RCT. A1C analysis included all randomized
participants who completed at least one post-

RESULTS
RCT
Participant disposition and study design appear in Figure 1. The Paper (n  92) and Electronic (n  113) Groups had similar demographic characteristics, including gender
distribution, type of diabetes, ethnicity, age,
years since diagnosis, years of SMBG, and monitoring frequencies (Table 1). The Paper and
Electronic Groups had similar mean A1C values at enrollment (SV1; 9.13  0.91% vs. 9.06 
1.29%) and similar mean reductions from enrollment to randomization (SV2; 0.17 
0.45% vs. 0.17  0.40%). From randomization
through the end of the RCT, mean A1C decreased 0.27% in the Paper Group and
0.35% in the Electronic Group (Fig. 2). Repeated-measures analysis showed that the
mean decrease over this time period was significantly greater in the Electronic Group than
in the Paper Group (P  0.022). An analysis of
pediatric patients (n  70) showed similar results favoring participants in the Electronic
Group (P  0.024).
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FIG. 1. Design of the RCT and observational follow-up. *A1C at SV2 more than 1.0% different from A1C at SV1.
†One became pregnant; five enrolled in another study involving unknown medications that may have affected BG
values.

At enrollment, the reported SMBG frequency
was similar in the two groups, with 58% in the
Paper Group and 59% in the Electronic Group
monitoring four or more times per day. From
randomization through the end of the RCT, the
documented average daily SMBG frequency
was significantly greater in the Electronic
Group (4.0  1.5 times per day) than in the Paper Group (3.5  1.5 times per day) with 48%
of the Electronic Group compared to 30% of the
Paper Group monitoring four or more times
daily (2  8.92, df  3, P  0.03).
Mean Amplitude of Glycemic Excursions
(MAGE) did not differ significantly between
groups, with daily glycemic excursions gener-

ally exceeding 200 mg/dL. However, the rate
of measured hypoglycemic events was significantly lower in the Paper Group than in the
Electronic Group (1.0 vs. 1.5 events per week,
P  0.0001), although no episodes of severe hypoglycemia were reported in either group.
Observational follow-up
Disposition of the 104 patients who returned
for SV7 appears in Figure 1; there were no significant baseline inter-subgroup differences
(Table 1). Mean A1C at randomization (SV2)
was similar in the four subgroups (Table 1). Between SV2 and SV7, mean A1C decreased by
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TABLE 1.

Age (years)
Gender (male)
Diagnosis
Type 1
Type 2
Duration of diabetes
(years)
Frequency of SMBG
(times/day)
A1C (%)

BASELINE DEMOGRAPHIC CHARACTERISTICS FOR PARTICIPANTS ACCORDING
TO GROUP ASSIGNMENT AND BY SV7 SUBGROUP

Paper group
(n  92)

Subgroup 1a
(n  28)

Subgroup 1b
(n  23)

Electronic group
(n  113)

Subgroup 2a
(n  42)

Subgroup 2b
(n  11)

35.0  18.7
42 (45.7%)

32.5  18.6
10 (35.7%)

32.6  19.0
12 (52.2%)

35.7  19.7
49 (43.4%)

32.9  18.6
17 (40.5%)

28.8  18.5
3 (27.3%)

73 (79.4%)
19 (20.6%)
14.0  10.0

22 (78.6%)
6 (21.4%)
11.9  9.4

20 (87.0%)
3 (13.0%)
14.4  10.1

90 (79.6%)
23 (20.4%)
13.3  10.3

38 (90.5%)
4 (9.5%)
12.5  10.3

9 (81.8%)
2 (18.2%)
13.2  10.4

3.8  1.2

3.6  1.0

3.9  1.3

3.9  1.4

3.9  1.2

3.8  1.3

9.13  0.91

9.05  1.01

9.32  0.87

9.06  1.29

8.96  0.96

9.21  1.44

Data are mean  SD values or number (%) as indicated.

0.36  0.13% (P  0.008) in those who continued using the integrated meter/logbook
from the RCT through the follow-up visit
(Group 2a), but increased in the other three
groups, 0.32  0.20% in those who used conventional meters and logbooks throughout
(Group 1a, P  0.118), 0.04  0.28% in those
who switched from electronic to conventional
meters and logbooks (Group 2b, P  0.899),
and 0.01  0.19% in those who switched from
conventional to electronic meters/logbooks
(Group 1b, P  0.964). The difference between
those who used conventional meters and logbooks throughout (Group 1a) and those who
used integrated meters/logbooks throughout
(Group 2a) was statistically significant (Fig. 3,
P  0.006). A similar trend in mean A1C differences was observed between pediatric patients who used conventional meters and paper logbooks throughout and those who used
integrated meters/logbooks throughout (P 
0.053). Between the end of the RCT and the follow-up visit (SV6 to SV7), A1C increased in all
four groups: 0.35  0.18% in Group 1a (P 
0.058), 0.41  0.25% in Group 1b (P  0.122),
0.11  0.11% in Group 2a (P  0.317), and
0.29  0.28% in Group 2b (P  0.326).
Of the 65 patients who used the electronic
logbook (Groups 1b and 2a), 33 reported reviewing screens with their HCP. Between the
end of the RCT and SV7, the A1C increase in
patients who did not review screens with their
HCP was greater than in those who did review
screens (0.42  0.21% vs. 0.02  0.09%, P 
0.052) (Fig. 4).

DISCUSSION
These results demonstrate that, both during
an RCT and during an observational follow-up
period of routine care without the added support of a trial, use of an integrated meter/logbook was associated with improved glycemic
control when compared with use of conventional meters and paper logbooks. Participants
using the integrated meter/logbook monitored
more frequently, which may have motivated
positive behavioral changes or provided additional information on which they could take action to improve glycemic control. The automated formatting of accurate data may have
resulted in better decision-making by participants or HCPs. Among participants who used
the integrated meter/logbook, those who reviewed their screens with their HCPs tended
toward better glycemic control than those who
did not, suggesting that active engagement
with the electronic logbook may have been beneficial.
While significant, both the difference between
the two groups at the end of the RCT and the
absolute reductions in A1C from baseline were
modest. This was not surprising, considering the
modest nature of the intervention and the relatively short length of the RCT. The participants
included in this trial, with high initial A1C levels, may have been particularly challenged in
their ability to change behaviors without significant intervention.24 However, as shown in several landmark clinical trials, any reduction in
A1C reduces the risks of complications.1–5,25
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A

B

FIG. 2. (A) Mean A1C at each study visit during the RCT. Participants were enrolled at SV1 (week 0) and randomized at SV2 (week 4). In the Paper Group, there were 92 patients at SV1 and SV2, 90 at SV3, 84 at SV4, 86 at SV5, and
86 at SV6. In the Electronic Group, there were 113 patients at SV1, 111 at SV2, 110 at SV3, 108 at SV4 and SV5, and
107 at SV6. (B) Mean decrease in A1C during the RCT from time of randomization (SV2).

A

B

FIG. 3. (A) Mean A1C for patients completing the observational follow-up, by subgroup. Two patients, one each
from Groups 1a and 1b, were not present for SV4, and two patients, one each from Groups 1b and 2a, were not present for SV5. The follow-up study visit occurred between weeks 46 and 85 (median week 65.9). (B) Mean decrease in
A1C from time of randomization (SV2).
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A

B

FIG. 4. (A) Mean A1C for patients using the integrated meter/logbook through SV7 (Groups 1b and 2a) who reported reviewing screens or not reviewing screens with their HCPs. The follow-up study visit occurred between weeks
46 and 85 (median week 65.9). (B) Mean decrease in A1C from time of randomization (SV2).

262

The Paper Group’s reduction in A1C during
the run-in period and RCT may be related to
positive behavior changes associated with being observed in a clinical trial and receiving additional support and free monitoring supplies,
as has been consistently observed in other glucose monitoring trials.24,26,27 However, when
patients return to usual care following a clinical trial, they tend to relapse into old habits,
and glycemic benefits disappear.5 This tendency was observed during the non-trial, observational period, as patients in three of the
four subgroups returned to pre-trial A1C levels, whereas patients who continued with the
integrated meter/logbook maintained their
significant A1C reduction from baseline. The
greater divergence of the Paper and Electronic
Groups after the RCT suggests a glycemic advantage from using an electronic logbook. In
addition to the ease with which BG data are
displayed in the electronic logbook, it may also
reduce patient burden by removing the need to
maintain a written logbook.
The issuance of a new device to a single arm
of the study (the Electronic Group) may have
exaggerated the glycemic benefit attributed to
this group during the RCT. This effect, however, would not likely have been maintained
over an extended period in a real-world setting,
contrary to what was observed during followup. Furthermore, patients who switched to
electronic meters/logbooks after the RCT experienced an increase in A1C to pre-trial levels
during the follow-up period. Unlike participants initially randomized to the Electronic
Group, those who switched to integrated meters/logbooks during the observational period
did not receive standardized training, instruction to review screens with their HCPs, or
monthly reinforcement, indicating that appropriate training and engagement with the electronic logbook may be a requisite for achieving
or sustaining improved glycemic control with
any new technology.
Routine meter downloading and analysis
are complex and labor and time intensive. Although downloaded results may aid in treatment guidance, most HCPs do not routinely
download glucose meter data.28 Accordingly,
the protocol for the RCT did not allow routine
downloading of results in either arm, and the
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beneficial effect on glycemic control observed
in the Electronic Group was likely associated
with the data available to patients and/or the
HCPs in the absence of downloading. Similar
benefits may have been attainable by downloading conventional meters to appropriate
diabetes management software during the
RCT. However, although meter downloading
was permitted during the observational follow-up period, only participants who continued to use the integrated meter/logbook
maintained their improvement in glycemic
control.
This study warrants additional comments regarding limitations. The length of the RCT was
relatively short, and A1C levels in both groups
were still declining at the last study visit (SV6),
suggesting the possibility of a more robust effect in a longer study, particularly one with
monthly follow-up. In addition, because of the
nature of this trial, neither patients nor their
HCPs could be fully blinded to group assignment, possibly leading to unintended bias.
Next, the greater reduction in A1C in the Electronic Group may have yielded a greater number of measured hypoglycemic episodes.
Alternatively, the increased detection of hypoglycemic episodes in the Electronic Group may
have resulted from more frequent BG monitoring and greater ascertainment of events
rather than from an actual increase in events
relative to the Paper Group. Finally, the choice
to continue with or switch monitoring systems
during the observational period was left to the
patients and their HCPs, introducing the possibility of selection bias.
In conclusion, these results demonstrate that
insulin-treated participants using integrated
meters and electronic logbooks were able to improve glycemic control when compared to participants using conventional meters and paper
logbooks. Moreover, patients using integrated
meters and electronic logbooks were able to
maintain significant glycemic improvements
during long-term follow-up in a real-world setting, beyond the controlled conditions of a clinical trial. Sustained improvements in glycemic
control will likely serve to preserve health and
reduce the risks of future complications; additional studies are needed to confirm these findings.
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